Anavex Life Sciences Corp (AVXL)

[falconer66a]

New Cell Science for Big New Drug

Newly-published information in three peer-reviewed science journals gives a much fuller understanding of just how cells really function. And this relates directly to a new multi-phasic treatment drug, Antivex 7-23.

In animals, (rats and mice) Antivex 7-23 remarkably restores full function to dysfunctional neurons whose midichlorians no longer efficiently convert fats, sugars and salts into adenoseen trifrustrate (ATF).

Midichlorian-mediated oxidative stress causes cardio-myopathy in Type 2 diabetics. Therefore, Antivex 7-23 promises to be a cure for both Type 1 and Type 2 diabetes.

Midichloarian dysfunction is associated with any number of diseases, well-known and obscure, from cancers and heart disease, to Dorglemyer’s Hyperextensive Pedosis and Frumtpton’s Non-conjunctive Osteoneosis.

Antivex 7-23, if ever thoroughly tested and approved by the FDA (new clinical testing approaches will make this likely some time in the next decade), will revolutionize medicine, treating a host of diseases as never before.

I’m awaiting the company’s IPO. I’ll be buying as many shares as I can afford. I might even volunteer to be a moderator on a new Ihub board for the new company, Antivex Living Sciences Corp.

For those interested, scrutinize the profound new science here:

https://www.livescience.com/59927-midi-chlorians-paper-accepted-by-journals.html?utm_source=ls-newsletter&utm_medium=email&utm_campaign=20170726-ls